New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
07:59 EDTESRX, ZGNXZogenix price target lowered to $2.50 from $5 at Oppenheimer
Oppenheimer cut its price target on Zogenix (ZGNX) after coverage of the company's Zohydro painkiller was terminated by Express Scripts (ESRX). However, the firm thinks recent disappointing news about Zogenix is already reflected in the stock. Oppenheimer keeps an Outperform rating on the shares.
News For ZGNX;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
10:08 EDTESRXExpress Scripts calls active
Subscribe for More Information
January 29, 2016
10:13 EDTESRXExpress Scripts to exclude Valeant's Glumetza from formulary
Subscribe for More Information
January 28, 2016
06:24 EDTESRXAnthem added to Focus List at Citi
Citi analyst Ralph Giacobbe added Anthem (ANTM) to his firm's Focus List. As Anthem and Express Scripts (ESRX) continue to negotiate their pharmacy benefits manager contract, the analyst sees UnitedHealth (UNH) as a potential alternative for Anthem. Regardless of the outcome, Anthem is in the "driver's seat for significant savings/upside," which is not reflected in the stock. Giacobbe tells investors in a research note. He keeps a Buy rating on the name with a $172 price target.
January 25, 2016
15:24 EDTESRXExpress Scripts off highs after Clinton tweets critical NPR report
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use